DHL Supply Chain is expanding its pharmaceutical and medical device distribution network by 40% this year with an investment of US$150 million. With this expansion, the American contract logistics company will have a total of 30 sites designed to support pharmaceutical, biotech, and medical device companies.
DHL is planning nine new sites by the end of 2019. The investment includes costs to invest in new buildings and technology, as well as the fit-out and start-up of new or expanded operations.
The expansion brings the total number of sites dedicated to compliant pharmaceutical and medical device distribution to 30. The business is taking many measures to prepare for future growth. These include new market investments in Indianapolis, and Raleigh, NC; multiple new facilities in key campus markets such as Memphis, and South Central, Pa.; and new sites in California and Virginia.
“This expansion allows DHL Supply Chain to continue to deepen the connections between our customers and the patients they serve,” said Scott Cubbler, President of Life Sciences & Healthcare at DHL Supply Chain. “This most recent expansion also helps us leverage differentiated routes to market, driving even greater efficiency and productivity across the supply chain for our customers.”
These sites, strategically located within the US, are fully licensed with temperature controlled space that supports pharmaceutical storage requirements. The sites also allow for packaging and managed transportation for integrated solutions.